Literature DB >> 21979184

Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis.

Lina Lindström1, Annika Lapidus, Ake Ost, Annika Bergquist.   

Abstract

BACKGROUND: Almost 10% of all patients with primary sclerosing cholangitis receive a diagnosis of Crohn's disease. Clinical characteristics and the risk of colon cancer or dysplasia in Crohn's disease and primary sclerosing cholangitis are less well examined than in ulcerative colitis.
OBJECTIVE: This study aimed to describe the clinical characteristics and risk of colorectal dysplasia and cancer in Crohn's disease in patients with primary sclerosing cholangitis.
DESIGN: This is a cohort study of all patients diagnosed with primary sclerosing cholangitis and colorectal Crohn's disease at Karolinska University Hospital, Huddinge, 1978 to 2006. Each patient was matched for age and the onset of Crohn's disease to 2 controls with colorectal Crohn's disease without liver disease.
SETTING: This study was conducted at a tertiary referral center. PATIENTS: Twenty-eight patients (61% male) with primary sclerosing cholangitis and Crohn's disease and 46 patients (50% male) with Crohn's disease alone were studied. Clinical and endoscopic data were retrieved from medical records. Colonic biopsies from patients with primary sclerosing cholangitis were re-reviewed. MAIN OUTCOME MEASURES: The primary outcome measured was the proportion of patients developing colorectal cancer.
RESULTS: Colorectal cancer or dysplasia developed in 9 patients with primary sclerosing cholangitis and in 3 controls. Patients with primary sclerosing cholangitis were more likely to develop colorectal dysplasia or cancer than controls (OR 6.78; 95% CI (1.65-27.9); P = .016). In patients with primary sclerosing cholangitis compared with controls, perianal fistulas occurred in 3% vs 33% (P = .003), bowel strictures occurred in 7% vs 30% (P = .03), and bowel surgery was performed in 18% vs 46% (P = .01). Histological granulomas were seen in 29% of the patients with primary sclerosing cholangitis compared with 43% in controls (P = not significant). LIMITATIONS: This study was limited by its retrospective nature and the limited cohort.
CONCLUSIONS: Primary sclerosing cholangitis is a risk factor for the development of colorectal cancer and dysplasia in Crohn's disease. Obstructing disease and perianal fistulas are rare in primary sclerosing cholangitis and less common than in colonic Crohn's disease without liver disease.

Entities:  

Mesh:

Year:  2011        PMID: 21979184     DOI: 10.1097/DCR.0b013e31822bbcc1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  19 in total

1.  Survival of Colorectal Cancer in Patients With or Without Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Baochi Ou; Jingkun Zhao; Shaopei Guan; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

Review 2.  Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.

Authors:  Rosy Wang; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 3.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 4.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

Review 5.  Crohn's Disease and the Risk of Cancer.

Authors:  Evie Carchman
Journal:  Clin Colon Rectal Surg       Date:  2019-07-02

6.  Primary Sclerosing Cholangitis: Current and Future Management Strategies.

Authors:  John E Eaton; Jayant A Talwalkar
Journal:  Curr Hepat Rep       Date:  2013-03-01

7.  Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-07

Review 8.  Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?

Authors:  Nick E Burr; Mark A Hull; Venkataraman Subramanian
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

9.  Circulating CD4+CD25+ regulatory T cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis.

Authors:  Murat Kekilli; Bilge Tunc; Yavuz Beyazit; Mevlut Kurt; Ibrahim Koral Onal; Aysel Ulker; Ibrahim Celalettin Haznedaroglu
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

10.  Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.

Authors:  Mohamed Attauabi; Mirabella Zhao; Flemming Bendtsen; Johan Burisch
Journal:  Therap Adv Gastroenterol       Date:  2021-06-22       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.